UM Today UM Today University of Manitoba UM Today UM Today UM Today
News from
Research and International
UM Today Network
Lorrie Kirshenbaum

Lorrie Kirshenbaum

Cancer treatment without toxic effects

December 9, 2014 — 

The drug Doxorubicin (DOX) may be an effective anticancer treatment, but like other anthracyclines it has a toxic effect on the heart — a considerable limitation. Lorrie Kirshenbaum, principal investigator, Cardiac Gene Biology, Institute of Cardiovascular Sciences at St-Boniface Hospital Research Centre, professor of physiology, and Canada Research Chair, Molecular Cardiology, University of Manitoba, has just published evidence of a protein mechanism apparently responsible for the side effect. His laboratory results recently showed that when this protein is “knocked out” the cancer treatment can proceed — without damaging the heart.

Kirshenbaum’s publication, “Bnip3 mediates doxorubicin-induced cardiac myocyte necrosis and mortality through changes in mitochondrial signalling,” was published this week in Proceedings of the National Academy of Sciences.

“Our findings have important clinical implications not only for preventing heart failure by targeting a specific protein in cancer patients undergoing chemotherapy, but also for understanding other diseases in which cell function is compromised,” says Kirshenbaum.

“It is well established that cancer patients undergoing DOX treatment are susceptible to acute and chronic cardiac side effects, including arrhythmias, ventricular dysfunction and heart failure” says Davinder Jassal, a cardiologist at St-Boniface Hospital and one of several co-authors of the publication. “Finding the pathway to this additional disease process is the first step to developing effective treatment”.

Professor Andre Terzic, Director of the Mayo Clinic Center for Regenerative Medicine, agrees. “This comprehensive work is exciting. By resolving the molecular underpinnings of cardiotoxicity induced by the anti-cancer drug doxorubicin, this study underscores the promise of targeted mitochondrial medicine for heart failure prevention in the context of chemotherapy” says Terzic.

“We are very proud of what Dr. Kirshenbaum and his laboratory have accomplished at St-Boniface Hospital Research. His results will undoubtedly push research to the next step of resolving this devastating side effect,” says Grant Pierce, executive director of research at St-Boniface Hospital.

 

Research at the University of Manitoba is partially supported by funding from the Government of Canada Research Support Fund.

, ,

Leave a Reply

Your email address will not be published. Required fields are marked *

© University of Manitoba • Winnipeg, Manitoba • Canada • R3T 2N2

Emergency: 204-474-9341

Top